Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD - CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s Proprietary SCS Microinjector® - - Topline Data Expected to be Reported During the Week of October 7, 2024 - ALPHARETTA, Ga., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced the completion of the fina...
Ring Energy Announces Participation In Enercom Denver Conference THE WOODLANDS, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today announced its participation in the EnerCom Denver Conference to be held in Denver, Colorado where Paul McKinney, Chairman and Chief Executive Officer, is scheduled to make a presentation on Monday, August 19th, 2024 at 11:20 am Mountain Time (12:20 pm Central Time). Senior management will also host one-on-one meetings with investors. The presentation will be webcast live and archived on Ring’s websi...
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse Events Observed - - Recent Key Opinion Leader Webinar Highlighted the Broad Applicability and Real-World Experience of Suprachoroidal Drug Delivery - ALPHARETTA, Ga., Aug. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the...
Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that management will present a corporate update at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference which will be available on demand on Thursday, August 15, 2024, at 7:00 a.m. ET. Victor Chong, MD, MBA, Chief Medical Officer, will also pa...
Ring Energy Announces Second Quarter 2024 Results, Provides Guidance for Third Quarter and Updates Full Year 2024 Outlook THE WOODLANDS, Texas, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today reported operational and financial results for second quarter 2024 and provided an improved outlook for the third quarter and full year. Second Quarter 2024 Highlights Produced sales of 13,623 barrels of oil per day (“Bo/d”), representing a 2% increase over the first quarter of 2024;Sold record total volumes of 19,786 barrels of oil equiv...
Ring Energy Provides Management Team Update THE WOODLANDS, Texas, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today announced a management team update, including the addition of a new senior executive. Mr. Phillip Feiner has joined Ring as Vice President, General Counsel. With more than 25 years of energy industry experience, including with both public and private companies, Mr. Feiner is responsible for leading Ring’s legal and human resources efforts. Mr. Paul D. McKinney, Chairman of the Board and Chief Executive Officer, comment...
Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024 ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2024 financial results will be reported on Monday, August 12, 2024, after the close of the financial markets. In lieu of a second quarter 2024 conference call, the Company hosted a Suprachoroidal Delivery Key Opinion Leader Webina...
Ring Energy Announces Timing of Second Quarter 2024 Earnings Release and Conference Call THE WOODLANDS, Texas, July 30, 2024 (GLOBE NEWSWIRE) -- Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today announced the timing of its second quarter 2024 earnings release and conference call. Ring plans to issue its second quarter 2024 earnings release after the close of trading on Tuesday, August 6, 2024. The Company has scheduled a conference call on Wednesday, August 7, 2024 at 11:00 a.m. central to discuss its second quarter 2024 operational and financial results. To particip...
Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China Primary and Secondary Endpoints Achieved with Favorable Tolerability and Safety Profile ALPHARETTA, Ga., July 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that its partner, Arctic Vision, reported positive topline results from its Phase 3...
Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), has opened registration for its virtual key opinion leader (KOL) event on Wednesday, July 24, 2024 from 8:00 - 9:15 am ET. To register for the event, . The event will highlight the broad applicability and real-world experience with s...
Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the C...
On July 8, 2024, Ring increased its 2Q24 production guidance to 13.5-13.7 MB/d of oil (19.5-19.7 MBOE/d) from 13.0-13.4 MB/d of oil (18.5-19.1 MBOE/d) reflecting the continuation of outperformance exhibited in 1Q24 (Figure 1). Production volumes are benefiting from outperformance in Ring’s development program and increased operational efficiencies in the company’s base production. The midpoint reflects gains of ~2% Q/Q and 15% Y/Y. The Y/Y gain partially reflects the addition of assets acquired ...
Ring Energy Increases Sales Guidance and Announces Debt Reduction Results for Second Quarter 2024 Reaffirms Borrowing Base at $600 Million THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today updated second quarter of 2024 sales guidance and end-of-period debt, and announced reaffirmation of the $600 million borrowing base. Key Highlights Increases second quarter 2024 sales guidance range above its high end of prior guidance for both barrels of oil per day (“Bopd”) and barrels of oil equivalent per day (“Boepd”)...
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery - Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ALPHARETTA, Ga., June 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye thro...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.